Gui-Ming Zhang1,2, Yao Zhu1,2, Wei-Jie Gu1,2, Hai-Liang Zhang1,2, Guo-Hai Shi1,2, Ding-Wei Ye3,4. 1. Department of Urology, Fudan University, Shanghai Cancer Center, No. 270, Dong'an Rd, Shanghai, 200032, People's Republic of China. 2. Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China. 3. Department of Urology, Fudan University, Shanghai Cancer Center, No. 270, Dong'an Rd, Shanghai, 200032, People's Republic of China. yedingwei1963@126.com. 4. Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China. yedingwei1963@126.com.
Abstract
BACKGROUND: The neutrophil-to-lymphocyte ratio (NLR) is associated with clinical outcomes of various cancers. This study aimed to evaluate whether pretreatment NLR can be used as a prognostic factor in patients with metastatic renal cell carcinoma (mRCC) receiving targeted therapy. METHODS: In this single-center retrospective study, the Kaplan-Meier method was used to estimate progression-free survival (PFS) and overall survival (OS) of 373 mRCC patients receiving targeted therapy. The survival outcomes of patients with high (≥ 2.2) and low (< 2.2) pretreatment NLRs were compared by log-rank test, and Cox proportional hazard regression model was used to compare OS and PFS between groups. RESULTS: The overall median PFS and OS times for all 373 patients were 18.4 and 34.3 months, respectively. Patients with high NLRs had significantly shorter median OS (28.8 vs 410 months, P = 0.005) and PFS (15.4 vs 23.9 months, P = 0.001) than those with low NLRs. After adjusting for confounding variables, each unit increase of NLR was associated with a 40 % increase in mortality (hazard ratio [HR] 1.391; 95 % confidence interval [CI] 1.022-1.894; P = 0.036). High NLR was also an independent predictor of poor PFS (HR 1.544; 95 % CI 1.166-2.045; P = 0.002). CONCLUSION: Pretreatment NLR may be an independent prognostic factor for mRCC patients who are receiving targeted therapy.
BACKGROUND: The neutrophil-to-lymphocyte ratio (NLR) is associated with clinical outcomes of various cancers. This study aimed to evaluate whether pretreatment NLR can be used as a prognostic factor in patients with metastatic renal cell carcinoma (mRCC) receiving targeted therapy. METHODS: In this single-center retrospective study, the Kaplan-Meier method was used to estimate progression-free survival (PFS) and overall survival (OS) of 373 mRCC patients receiving targeted therapy. The survival outcomes of patients with high (≥ 2.2) and low (< 2.2) pretreatment NLRs were compared by log-rank test, and Cox proportional hazard regression model was used to compare OS and PFS between groups. RESULTS: The overall median PFS and OS times for all 373 patients were 18.4 and 34.3 months, respectively. Patients with high NLRs had significantly shorter median OS (28.8 vs 410 months, P = 0.005) and PFS (15.4 vs 23.9 months, P = 0.001) than those with low NLRs. After adjusting for confounding variables, each unit increase of NLR was associated with a 40 % increase in mortality (hazard ratio [HR] 1.391; 95 % confidence interval [CI] 1.022-1.894; P = 0.036). High NLR was also an independent predictor of poor PFS (HR 1.544; 95 % CI 1.166-2.045; P = 0.002). CONCLUSION: Pretreatment NLR may be an independent prognostic factor for mRCC patients who are receiving targeted therapy.
Authors: Benoit Beuselinck; Yann-Alexandre Vano; Stéphane Oudard; Pascal Wolter; Robert De Smet; Lore Depoorter; Corine Teghom; Alexandra Karadimou; Jessica Zucman-Rossi; Philip R Debruyne; Hendrik Van Poppel; Steven Joniau; Evelyne Lerut; Michiel Strijbos; Herlinde Dumez; Robert Paridaens; Ben Van Calster; Patrick Schöffski Journal: BJU Int Date: 2014-01-15 Impact factor: 5.588
Authors: Daniel Y C Heng; Wanling Xie; Meredith M Regan; Lauren C Harshman; Georg A Bjarnason; Ulka N Vaishampayan; Mary Mackenzie; Lori Wood; Frede Donskov; Min-Han Tan; Sun-Young Rha; Neeraj Agarwal; Christian Kollmannsberger; Brian I Rini; Toni K Choueiri Journal: Lancet Oncol Date: 2013-01-09 Impact factor: 41.316
Authors: Daniel Y C Heng; Wanling Xie; Meredith M Regan; Mark A Warren; Ali Reza Golshayan; Chakshu Sahi; Bernhard J Eigl; J Dean Ruether; Tina Cheng; Scott North; Peter Venner; Jennifer J Knox; Kim N Chi; Christian Kollmannsberger; David F McDermott; William K Oh; Michael B Atkins; Ronald M Bukowski; Brian I Rini; Toni K Choueiri Journal: J Clin Oncol Date: 2009-10-13 Impact factor: 44.544
Authors: M Santoni; U De Giorgi; R Iacovelli; A Conti; L Burattini; L Rossi; S Luca Burgio; R Berardi; G Muzzonigro; E Cortesi; D Amadori; S Cascinu Journal: Br J Cancer Date: 2013-09-05 Impact factor: 7.640
Authors: M Pichler; G C Hutterer; C Stoeckigt; T F Chromecki; T Stojakovic; S Golbeck; K Eberhard; A Gerger; S Mannweiler; K Pummer; R Zigeuner Journal: Br J Cancer Date: 2013-02-05 Impact factor: 7.640
Authors: Mehmet Asim Bilen; Giselle Marie Almeida Dutcher; Yuan Liu; Deepak Ravindranathan; Haydn T Kissick; Bradley C Carthon; Omer Kucuk; Wayne B Harris; Viraj A Master Journal: Clin Genitourin Cancer Date: 2018-01-04 Impact factor: 2.872
Authors: Angelina Tjokrowidjaja; David Goldstein; H Malcolm Hudson; Sarah J Lord; Val Gebski; Stephen Clarke; Paul de Souza; Robert J Motzer; Chee Khoon Lee Journal: Acta Oncol Date: 2019-08-29 Impact factor: 4.089